BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santoro L, Pitalot L, Trauchessec D, Mora-Ramirez E, Kotzki PO, Bardiès M, Deshayes E. Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res 2021;11:1. [PMID: 33394212 DOI: 10.1186/s13550-020-00737-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Piwowarska-bilska H, Kurkowska S, Birkenfeld B. Individualization of Radionuclide Therapies: Challenges and Prospects. Cancers 2022;14:3418. [DOI: 10.3390/cancers14143418] [Reference Citation Analysis]
2 Ramonaheng K, van Staden JA, du Raan H. Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms. Heliyon 2022;8:e09830. [PMID: 35865988 DOI: 10.1016/j.heliyon.2022.e09830] [Reference Citation Analysis]
3 Kennedy J, Chicheportiche A, Keidar Z. Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy. Semin Nucl Med 2021:S0001-2998(21)00091-X. [PMID: 34911637 DOI: 10.1053/j.semnuclmed.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Carter LM, Ocampo Ramos JC, Kesner AL. Personalized dosimetry of177Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomed Phys Eng Express 2021;7. [PMID: 34271565 DOI: 10.1088/2057-1976/ac1550] [Reference Citation Analysis]
5 Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, Schwarzenböck SM. Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers (Basel) 2021;13:3884. [PMID: 34359784 DOI: 10.3390/cancers13153884] [Reference Citation Analysis]